Puma Biotechnology Stock Filter Stocks by Fundamentals
| PBYI Stock | USD 3.23 0.09 2.87% |
Puma Biotechnology fundamentals help investors to digest information that contributes to Puma Biotechnology's financial success or failures. It also enables traders to predict the movement of Puma Stock. The fundamental analysis module provides a way to measure Puma Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Puma Biotechnology stock.
Puma | Shares Owned by Institutions |
Puma Biotechnology Current Valuation Drivers
We derive many important indicators used in calculating different scores of Puma Biotechnology from analyzing Puma Biotechnology's financial statements. These drivers represent accounts that assess Puma Biotechnology's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Puma Biotechnology's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 339.2M | 406.1M | 123.5M | 189.0M | 204.1M | 193.9M | |
| Enterprise Value | 399.5M | 441.7M | 177.1M | 227.1M | 231.0M | 219.4M |
Puma Biotechnology ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Puma Biotechnology's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Puma Biotechnology's managers, analysts, and investors.Environmental | Governance | Social |
Puma Biotechnology Institutional Holders
Institutional Holdings refers to the ownership stake in Puma Biotechnology that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Puma Biotechnology's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Puma Biotechnology's value.| Shares | Kennedy Capital Management Inc | 2024-09-30 | 593 K | State Street Corp | 2024-06-30 | 514 K | Globeflex Capital, L.p. | 2024-09-30 | 452.6 K | Connor Clark & Lunn Inv Mgmt Ltd | 2024-06-30 | 354.5 K | Northern Trust Corp | 2024-09-30 | 317.7 K | Bank Of New York Mellon Corp | 2024-06-30 | 309 K | Winton Capital Group Ltd | 2024-09-30 | 309 K | Sei Investments Co | 2024-06-30 | 289.5 K | Qube Research & Technologies | 2024-06-30 | 273.2 K | Vanguard Group Inc | 2024-09-30 | 3.6 M | Blackrock Inc | 2024-06-30 | 3.6 M |
Puma Fundamentals
| Return On Equity | 0.42 | ||||
| Return On Asset | 0.0973 | ||||
| Profit Margin | 0.1 % | ||||
| Operating Margin | 0.27 % | ||||
| Current Valuation | 143.78 M | ||||
| Shares Outstanding | 49.09 M | ||||
| Shares Owned By Insiders | 15.14 % | ||||
| Shares Owned By Institutions | 67.78 % | ||||
| Number Of Shares Shorted | 2.98 M | ||||
| Price To Earning | 18.52 X | ||||
| Price To Book | 2.17 X | ||||
| Price To Sales | 0.65 X | ||||
| Revenue | 235.64 M | ||||
| Gross Profit | 172.94 M | ||||
| EBITDA | 47.52 M | ||||
| Net Income | 21.59 M | ||||
| Cash And Equivalents | 77.96 M | ||||
| Cash Per Share | 1.71 X | ||||
| Total Debt | 111.49 M | ||||
| Debt To Equity | 5.19 % | ||||
| Current Ratio | 2.04 X | ||||
| Book Value Per Share | 1.45 X | ||||
| Cash Flow From Operations | 27.01 M | ||||
| Short Ratio | 6.44 X | ||||
| Earnings Per Share | 0.48 X | ||||
| Price To Earnings To Growth | 0.03 X | ||||
| Target Price | 4.33 | ||||
| Number Of Employees | 185 | ||||
| Beta | 1.08 | ||||
| Market Capitalization | 158.55 M | ||||
| Total Asset | 230.53 M | ||||
| Retained Earnings | (1.35 B) | ||||
| Working Capital | 56.8 M | ||||
| Current Asset | 223.55 M | ||||
| Current Liabilities | 32.44 M | ||||
| Net Asset | 230.53 M |
About Puma Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Puma Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Puma Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Puma Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Puma Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Puma Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Puma Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Puma Biotechnology Stock:Check out Puma Biotechnology Piotroski F Score and Puma Biotechnology Altman Z Score analysis. For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Puma Biotechnology. If investors know Puma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 2.417 | Earnings Share 0.48 | Revenue Per Share 5.045 | Quarterly Revenue Growth 0.435 | Return On Assets 0.0973 |
The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Puma Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Puma Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Puma Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.